Spots Global Cancer Trial Database for car
Every month we try and update this database with for car cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia | NCT05017883 | CAR Acute Myeloid L... | TAA05 cell inje... | 18 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| PSMA-specific CAR-T Cell Therapy | NCT04429451 | PSMA Positive T... | 4SCAR-PSMA T ce... | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | NCT04499339 | Multiple Myelom... | SLAMF7 CAR-T | 18 Years - | Wuerzburg University Hospital | |
| Induced-T Cell Like NK Cells for B Cell Malignancies | NCT04747093 | B Cell Leukemia B Cell Lymphoma B-cell Acute Ly... B-cell Lymphoma... B-cell Lymphoma... | CAR-ITNK cells | 18 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia | NCT05043571 | Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... Lymphoblastic L... CAR CAR T-Cell-Rela... Refractory Leuk... | CAR T-cell ther... | 6 Months - 65 Years | National University Hospital, Singapore | |
| ThisCART19A for B-NHL Relapsed After Auto-CAR T | NCT05691153 | CAR B Cell Lymphoma Relapsed Non-Ho... | ThisCART19A wit... ThisCART19A wit... | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | NCT03573700 | Acute Lymphobla... Acute Lymphobla... | Cyclophosphamid... Fludarabine Mesna CliniMACS CD19- specific ... | - 21 Years | St. Jude Children's Research Hospital | |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | NCT02414269 | Malignant Pleur... Mesothelioma Metastases Lung Cancer Breast Cancer | iCasp9M28z T ce... cyclophosphamid... pembrolizumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | NCT04499339 | Multiple Myelom... | SLAMF7 CAR-T | 18 Years - | Wuerzburg University Hospital | |
| TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia | NCT05017883 | CAR Acute Myeloid L... | TAA05 cell inje... | 18 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| A Phase I Trial of Anti-GD2 T-cells (1RG-CART) | NCT02761915 | Relapsed or Ref... | Leukapheresis Cyclophosphamid... Fludarabine 1RG-CART | 1 Year - | Cancer Research UK | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | NCT03744676 | Lymphoma, Non-H... Lymphoma Lymphoma, B-Cel... Lymphoma, Large... Neoplasms Neoplasms by Hi... Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... | lisocabtagene m... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma | NCT05054257 | Relapsed or Ref... Non-Hodgkin's L... Non-Hodgkin's L... | Autologous CAR1... | 18 Years - 80 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | NCT03267173 | Pancreatic Canc... CAR | Chimeric antige... | 18 Years - 65 Years | First Affiliated Hospital of Harbin Medical University | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors | NCT04691713 | CAR Solid Tumor | Targeting CD276... | 3 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia | NCT04692948 | CAR Acute Myeloid L... | Chimeric antige... | 18 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors | NCT04702841 | CAR Malignant Tumor... | Chimeric antige... | 14 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | NCT04499339 | Multiple Myelom... | SLAMF7 CAR-T | 18 Years - | Wuerzburg University Hospital | |
| Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | NCT02992210 | Solid Tumor | 4SCAR-GD2 | 1 Year - 65 Years | Shenzhen Geno-Immune Medical Institute | |
| CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors | NCT04691713 | CAR Solid Tumor | Targeting CD276... | 3 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
